ÂÜÀòÂÒÂ×

Dr. Talbot, an infectious diseases physician trained at the University of Pennsylvania Medical Center, began his pharmaceutical career in anti-infective drug development at Rhone-Poulenc Rorer, subsequently Aventis. He founded his consultancy firm, Talbot Advisors LLC, in 2000. Dr. Talbot later served as Executive Vice President/Chief Medical Officer of Cerexa Inc. (purchased by Forest Laboratories) and worked closely with the development teams at Calixa Therapeutics (acquired by Cubist Pharmaceuticals) and Durata Therapeutics (purchased by Actavis Plc). He was a founding member of IDSA's Antimicrobial Availability Task Force ("Bad Bugs, No Drugs"), recently sat on IDSA’s Antimicrobial Resistance Committee, was a committee member of the CLSI (previously NCCLS), and is past co-chair of the ABSSSI/CABP and HABP/VABP Clinical Trial Endpoint Development Project Teams at the Biomarkers Consortium of the Foundation of the National Institutes of Health. He has co-authored more than 100 publications in peer-reviewed scientific journals.